Securities Code: 002370 Securities Abbreviation: Asia-Pacific Pharmaceutical Announcement No.: 2026-031
Zhejiang Asia-Pacific Pharmaceutical Co., Ltd. Announcement on Changes in Accounting Policies
The Company and all members of the Board of Directors guarantee the truthfulness, accuracy, and completeness of the information disclosed, and are free from false records, misleading statements, or major omissions.
Zhejiang Asia-Pacific Pharmaceutical Co., Ltd. (hereinafter referred to as the "Company") held its 12th meeting of the 8th Board of Directors on April 23, 2026, and approved the "Proposal on Changes in Accounting Policies." This matter does not require submission to the shareholders' meeting for deliberation. The relevant situation is hereby announced as follows:
I. Overview of the Changes in Accounting Policies
- Reason and Effective Date of the Change in Accounting Policies
On December 5, 2025, the Ministry of Finance issued the "Notice on Issuing 'Interpretations of Accounting Standards for Business Enterprises No. 19'" (Cai Kuai [2025] No. 32), which stipulates the accounting treatment for compensatory assets in business combinations not under common control, the accounting treatment for relevant capital reserves when disposing of subsidiaries acquired through business combinations under common control, the termination of recognition of financial liabilities settled by electronic payment systems, the assessment of cash flow characteristics of financial assets and related disclosures, and the disclosure of equity instruments designated at fair value through other comprehensive income. These provisions are effective from January 1, 2026.